Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,100 result(s) found for: Non-Small Cell Lung Cancer (NSCLC). Displaying page 3 of 55.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-000612-30 Sponsor Protocol Number: D910MC00001 Start Date*: 2021-03-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curat...
    Medical condition: Completely resected stage II-III NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BG (Completed) BE (Completed) FR (Completed) GR (Completed) HU (Completed) CZ (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002552-24 Sponsor Protocol Number: PKAPIR Start Date*: 2016-12-16
    Sponsor Name:Centre Georges François Leclerc
    Full Title: Pemetrexed (Alimta®) in maintenance in patients with impaired renal function: multicenter randomized Phase 4 study comparing two strategies for dose calculation
    Medical condition: Patients with non-small lung cell cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008920-34 Sponsor Protocol Number: 09.01 Start Date*: 2009-03-19
    Sponsor Name:Odense University Hospital
    Full Title: Induction chemotherapy with Carboplatin and Navelbine Oral® followed by concomitant Navelbine Oral® and irradiation in local-regionally advanced non-small cell lung cancer. A randomized phase II s...
    Medical condition: Local-regionally advanced non-small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-001264-37 Sponsor Protocol Number: 1200.40 Start Date*: 2008-11-20
    Sponsor Name:BOEHRINGER ING.
    Full Title: A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients
    Medical condition: Patients affected by NSCLC EGFR FISH positive.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003250-15 Sponsor Protocol Number: 48/2008/O/Sper Start Date*: 2008-06-24
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: SEQUENTIAL CHEMOTHERAPY WITH CISPLATIN PLUS VINORELBINE FOLLOWED BY WEEKLY DOCETAXEL IN LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER
    Medical condition: locally advanced or metastatic NSCLC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000903-14 Sponsor Protocol Number: CRO685 Start Date*: 2007-07-17
    Sponsor Name:Imperial College, London
    Full Title: Randomized Phase III Trial to evaluate the effect of statins on tumour biology in non-small cell lung cancer.
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025050 Lung cancer non-small cell stage I LLT
    9.1 10025051 Lung cancer non-small cell stage II LLT
    9.1 10025052 Lung cancer non-small cell stage III LLT
    9.1 10025053 Lung cancer non-small cell stage IIIA LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012709-20 Sponsor Protocol Number: LF-0207 Start Date*: 2009-10-21
    Sponsor Name:Agennix Incorporated
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior...
    Medical condition: Non-small cell lung cancer in patients who have failed two or more prior treatment regimens.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) LV (Completed) FR (Ongoing) HU (Completed) DE (Completed) ES (Ongoing) GR (Completed) BG (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000201-44 Sponsor Protocol Number: IPI-504-14 Start Date*: 2011-08-26
    Sponsor Name:Infinity Pharmaceuticals, Inc
    Full Title: A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated patients with Stage IIIB or IV Non-Small Cell Lung Cancer
    Medical condition: Stage IIIB or IV Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-000711-85 Sponsor Protocol Number: MEF4984g Start Date*: 2011-10-17
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF MEGF0444A IN COMBINATION WITH CARBOPLATIN, PACLITAXEL AND BEVACIZUMAB IN PATIENTS ...
    Medical condition: ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025048 Lung cancer non-small cell recurrent LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025051 Lung cancer non-small cell stage II LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025046 Lung cancer cell type unspecified stage IV LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025050 Lung cancer non-small cell stage I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000556-35 Sponsor Protocol Number: D910LC00001 Start Date*: 2020-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected ...
    Medical condition: Completely Resected Stage II-III NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) DK (Prematurely Ended) BG (Completed) HU (Prematurely Ended) DE (Completed) BE (Completed) SE (Prematurely Ended) PL (Completed) CZ (Completed) GR (Completed) IT (Prematurely Ended) FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-005393-73 Sponsor Protocol Number: ERLOPET_01 Start Date*: 2007-09-14
    Sponsor Name:University Cologne
    Full Title: A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and t...
    Medical condition: The trial will be conducted in patients with non-small cell lung cancer in stage IIIb - IV
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000639-16 Sponsor Protocol Number: 9090-09 Start Date*: 2012-10-17
    Sponsor Name:Synta Pharmaceuticals Corp
    Full Title: A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non- Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)
    Medical condition: AKL positive advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2008-006486-88 Sponsor Protocol Number: Modafinil/lung/01 Start Date*: 2009-03-17
    Sponsor Name:University of Oxford
    Full Title: Modafinil for the treatment of fatigue in lung cancer: a multicentre, randomised, double-blinded, placebo-controlled trial
    Medical condition: The symptom of fatigue in patients with non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002941-20 Sponsor Protocol Number: GEST Start Date*: 2007-05-28
    Sponsor Name:SECONDA UNIVERSITA' DEGLI STUDI DI NAPOLI
    Full Title: RANDOMIZED PHASE II STUDY OF SORAFENIB PLUS GEMCITABINE OR SORAFENIB PLUS ERLOTINIB IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) ELDERLY OR PS 2 PATIENTS
    Medical condition: ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) ELDERLY OR PS 2 PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061873 PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001262-32 Sponsor Protocol Number: GMIHO-003/2006 Start Date*: 2007-05-21
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung c...
    Medical condition: NSCLC (Non-small Cell Lung Cancer) stage IIIB/IV
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000493-15 Sponsor Protocol Number: NVALT30 Start Date*: 2020-08-13
    Sponsor Name:Radboud University Medical Center
    Full Title: Dose tapering and Early Discontinuation to InCreAse cosT-effectIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1
    Medical condition: non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027412 Mesotheliomas HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003383-51 Sponsor Protocol Number: 2012/VCC/0037 Start Date*: 2013-06-26
    Sponsor Name:Velindre NHS Trust
    Full Title: A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with non-small cell lung cancer
    Medical condition: Non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002161-30 Sponsor Protocol Number: 1302.5 Start Date*: 2015-09-07
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Sm...
    Medical condition: Recurrent or metastatic disease (Stage IV), histologically or cytologically confirmed advanced nonsquamous Non-Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PT (Completed) ES (Completed) DE (Completed) PL (Completed) HR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005427-16 Sponsor Protocol Number: D4191C00003 Start Date*: 2014-07-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have receive...
    Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10066490 Progression of non-small cell lung cancer LLT
    17.0 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) BE (Trial now transitioned) AT (Completed) ES (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004009-32 Sponsor Protocol Number: A4061039 Start Date*: 2008-12-16
    Sponsor Name:PFIZER, S.A.
    Full Title: Estudio en fase 2 aleatorizado de cisplatino/pemetrexed con o sin axitinib (AG-013736) para el tratamiento en primera línea de pacientes con cáncer de pulmón no microcítico no escamoso.
    Medical condition: Cáncer de pulmón no microcítico no escamoso.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 17:45:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA